Bonnie Quach's questions to MEI Pharma (MEIP) leadership • Q4 2021
Question
Bonnie Quach of Stifel Financial Corp. inquired about the upcoming top-line data for the TIDAL study, asking what to expect regarding follow-up duration, the analysis of POD24 patients, and the rationale for selecting relapsed/refractory colorectal cancer (CRC) for the ME-344 trial.
Answer
Dan Gold, President and CEO, explained that the primary endpoint for the TIDAL readout is overall response rate (ORR) after a minimum of 6 months of treatment, with more precise durability data expected in the first half of the next year. He confirmed POD24 patients are being analyzed as an exploratory endpoint. For ME-344, the choice of third-line CRC was based on an advisory panel's consensus that it is a setting where Avastin is used but has low efficacy, presenting a clear opportunity to demonstrate improved patient outcomes.